Our results demonstrated that CA125 via the MSLN/DKK1/SGK3/FOXO3 pathway accelerates cell migration, and targeting mesothelin may potentially be utilized in ovarian cancer therapy. This evidence concerns the gene MUC16 and ovarian carcinoma.